Real‐world effectiveness of sotrovimab and remdesivir for early treatment of high‐risk hospitalized COVID‐19 patients: A propensity score adjusted retrospective cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28460
Abstract: Early treatment of high‐risk COVID‐19 patients may prevent disease progression. However, there are limited data to support treatment of hospitalized or fully vaccinated patients with mild‐to‐moderate disease. In this retrospective cohort study, we studied the… read more here.
Keywords: covid patients; sotrovimab; high risk; risk ... See more keywords
Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Reviews in Medical Virology"
DOI: 10.1002/rmv.2402
Abstract: The therapeutic potential of sotrovimab in the treatment of coronavirus disease 2019 (COVID‐19) is a controversial issue. The aim of this study was to evaluate the efficacy and safety of sotrovimab in COVID‐19 patients. To… read more here.
Keywords: efficacy safety; safety sotrovimab; sotrovimab; meta analysis ... See more keywords
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkac256
Abstract: Abstract Background Remdesivir and sotrovimab both have clinical trial data in the outpatient setting demonstrating reduction in the risk of hospitalizations and emergency department (ED) visits related to COVID-19. Objectives To evaluate the effectiveness of… read more here.
Keywords: risk covid; risk; sotrovimab; remdesivir sotrovimab ... See more keywords
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac282
Abstract: Abstract We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When… read more here.
Keywords: sotrovimab; high risk; real world; world experience ... See more keywords
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience
Sign Up to like & getrecommendations! Published in 2022 at "Transplantation"
DOI: 10.1097/tp.0000000000004150
Abstract: T he administration of monoclonal antibodies against SARS-CoV-2 reduce the risk of COVID-19–related hospitalization and death. 1 Solid organ transplant (SOT) patients with SARS-CoV-2 infection have higher rates of severe disease progression compared with the… read more here.
Keywords: sotrovimab; cov infection; organ transplant; solid organ ... See more keywords
Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Microbiology Spectrum"
DOI: 10.1128/spectrum.04103-22
Abstract: This study shows that among hospitalized patients with SARS-CoV-2 Omicron variant infection at risk of disease progression, treatment with sotrovimab alone or in combination with remdesivir did not decrease in-hospital mortality. These real-world clinical findings… read more here.
Keywords: omicron variant; sotrovimab; cov omicron; treatment ... See more keywords